Skip to content

Insulin-like Growth Factor Binding Protein 8 (IGFBP-8) Mass Concentration

Published: August 9, 2026Updated: August 16, 2026

This test measures the amount of IGFBP-8, a protein that helps regulate growth factors in your body. It may be used to assess hormone balance or metabolic health.

Quick summary

["IGFBP-8 helps control how growth factors work in your body, and levels can offer clues about certain health conditions."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
60005-6
Short code
IGF-I sp8 p chal SerPl-mCnc
Synonyms
IGF-I sp8 p chal SerPl-mCnc
Category
hormone
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Might Be Ordered

Your healthcare provider may recommend this test if you have symptoms or conditions linked to growth factors, such as growth disorders, metabolic syndrome, or suspected endocrine issues. It could also be part of a broader evaluation for conditions affecting hormone function or fluid balance.

What to Expect Before the Test

No special preparation is typically needed. You may provide a blood sample during a routine clinic visit or lab draw. If you’re taking certain medications or have recent trauma, let your provider know to ensure accurate results.

How the Test Works

Blood is drawn from a vein in your arm and sent to a lab. The lab uses a specialized technique to measure IGFBP-8 levels in your serum or plasma. This protein is part of a complex system that influences cell growth and metabolism.

What the Results Mean

Results are compared to general reference ranges, though individual values can vary based on age, sex, and health status. Elevated or low levels may signal underlying conditions that require further medical evaluation, such as growth hormone imbalances or metabolic disorders.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

IGFBP-8 plays a role in transporting and regulating insulin-like growth factors, which are critical for growth, tissue repair, and metabolism. Abnormal levels may be associated with conditions like growth hormone deficiencies, metabolic syndrome, or certain cancers. It can also help monitor treatment responses in hormone-related therapies.

Short name

IGFBP-8

Frequently asked questions

What does a high IGFBP-8 level mean?
High levels might indicate conditions affecting growth hormone regulation, such as certain tumors, liver disease, or metabolic disorders. Your provider will discuss findings in the context of your overall health and symptoms.
What does a low IGFBP-8 level mean?
Low levels could suggest growth hormone imbalances, kidney issues, or other metabolic disturbances. This result may prompt further testing or evaluation of your hormone or fluid balance.
Is fasting required for this test?
No fasting is usually required, but your provider may advise against certain foods or medications before testing if they could affect results.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy